Dnmt3a loss and Idh2 neomorphic mutations mutually potentiate malignant hematopoiesis

Area of Science:

• Hematology
• Cancer Biology
• Epigenetics

Background:

• Co-occurring mutations in DNMT3A and IDH1/2 are observed in acute myeloid leukemia (AML) and lymphoma.
• These mutations are implicated in the development of hematological malignancies.

Purpose of the Study:

• To investigate the cooperative effect of DNMT3A and IDH2 mutations in leukemogenesis.
• To identify potential therapeutic vulnerabilities in leukemia-initiating cells with these mutations.

Main Methods:

• Utilized Dnmt3a-/- mice expressing a neomorphic IDH2 mutant to model leukemia.
• Analyzed immunophenotype, gene expression, and epigenomic profiles (H3K9 methylation/acetylation) of hematopoietic stem and progenitor cells (HSPCs).
• Employed targeted metabolomic profiling and assessed the efficacy of HDAC inhibitors and prostaglandin synthesis inhibitors.

Main Results:

• Double-mutant leukemia-initiating cells exhibited a megakaryocyte-erythroid progenitor-like immunophenotype and repressed differentiated gene expression.
• Epigenomic dysregulation included increased H3K9 trimethylation and decreased H3K9 acetylation in diseased HSPCs.
• HDAC inhibitors reversed the epigenomic imbalance and reduced leukemia burden; prostaglandin E2 overproduction was identified, sensitizing cells to its synthesis inhibition.

Conclusions:

• DNMT3A and IDH2 mutations synergistically drive leukemogenesis.
• HSPCs with both mutations are sensitive to therapies targeting prostaglandin synthesis and HDAC activity, suggesting novel therapeutic avenues for AML patients with IDH mutations.